Your gateway to the world of medicine
Cancer News
About Us
Health Professionals
Patients and public
Contact Us

From How To Make Cox-2 Inhibitors Safer

Health news Asthma Hypertension  

Do You Read All Of Our Cancer Blogs?

Do You Read All Of Blogs?
Do you read all of the blogs published by Many of our bloggers are busy keeping you updated on the various health related topics. We publish the following blogs at this time.

Cancer blog: I manage the cancer blog with lots of help and support form other bloggers. Through this cancer blog my friends and I try to bring stories of hope for patients with cancer. The cancer blog often republishes important blog posts from other cancer related blogs at If you are searching for a blog that covers wide variety of cancer topics, this may be the one for you.

Breast cancer blog: Breast cancer blog is run by Emily and other bloggers and they bring you the latest stories, news and events that are related to breast cancer. Increasing awareness about breast cancer among women and in the general population is the main goal of this breast cancer blog.

Lung cancer blog: Lung cancer blog is managed by Scott with the help of other bloggers. Through this blog Scott and his friends constantly remind the readers about the dangers of smoking. It's a never-ending struggle against this miserable disease with which a social stigma of smoking is associated.

Colon cancer blog: Colon cancer blog is run by Sue and other bloggers. Sue brings a personal touch to the colon cancer blog since her mother died of colon cancer few years ago. She writes about stories, research news and advances in treatment related to colon cancer.

Prostate cancer blog: Prostate cancer is the most common cancer among American men. American Cancer Society estimates that over 230,000 new cases of prostate cancer occur in the United state every year. This important blog about prostate cancer is run by Mark and other bloggers. This blog brings news, stories, and other personal observations related to prostate cancer. publishes a diabetes watch blog and this blog is run by JoAnn other bloggers. This diabetes watch blog brings you the latest in the field of diabetes. This includes personal stories, advances in diagnosis and treatment, and other observations about diabetes. Improving awareness about diabetes is an important mission of this group.


How To Make Cox-2 Inhibitors Safer

How To Make Cox-2 Inhibitors Safer
A recently identified path of inflammation once thought to be wholly independent of other inflammatory systems has now been linked to another major pathway. The findings by neuroresearchers at Johns Hopkins are likely to point researchers to novel drugs that significantly reduce the risks of taking COX-2 inhibitor pain relievers, the researchers report.

In a paper published in the Dec. 23 issue of Science, a Johns Hopkins team led by Solomon H. Snyder, M.D., said the iNOS (inducible nitric oxide synthase)-based inflammation pathway has now been found to cross-link with the more well-known COX-2 pathway that is the target of COX-2 inhibitor drugs such as Vioxx. Until now, these two major inflammatory mechanisms were assumed to be unrelated and independent of each other, the scientists say.

"The fundamental significance of this work is that it demonstrates a totally unsuspected connection between the two most important inflammatory systems in the body," says Snyder, professor and director of neuroscience in Johns Hopkins' Institute for Basic Biomedical Sciences. "The therapeutic significance is that drugs which block the binding of iNOS and COX-2 might represent novel anti-inflammatory agents or reduce the dosage needed and side effects of this family of drugs".

COX-2 is an enzyme that makes prostaglandins, molecules that cause inflammation and pain. iNOS is an enzyme that makes NO (nitric oxide), a molecule that acts as a signal for a variety of cellular functions throughout the body, including the triggering of inflammation, dilating of blood vessels and penile erection.

The site on the iNOS protein that binds to COX-2 is close to the active or business end of the iNOS, the scientists found. As a result, it should be possible to design drugs that do double duty by inhibiting iNOS while also blocking iNOS binding to COX-2. This would decrease the formation of both NO and prostaglandins, Snyder said.

In addition to their studies in isolated cells, the team also demonstrated in mice the potential therapeutic role of drugs that block iNOS binding to COX-2. Specifically, they showed that in mice that lacked the gene for iNOS, production of a specific prostaglandin called PGE2 could be reduced by 70 percent.

"Now that we've characterized the iNOS-COX-2 inflammatory system and how to manipulate it, we have a road map for developing new drugs to treat inflammation and pain that permits simultaneous use of reduced dose levels of COX-2 inhibitors," Snyder says. "Our research suggests that the synergism between these two drugs would represent a highly effective and safer form of treatment.

"Blocking iNOS-COX-2 binding might salvage the value of COX-2 inhibitors by permitting the use of lower doses of these drugs, which have been shown to have troublesome potential side effects when used at their originally prescribed levels," Snyder added.

Scientists already knew that COX-2 can produce prostaglandins independently of iNOS. But the Hopkins study showed that iNOS is responsible for about half the total amount of prostaglandins that COX-2 produces in response to stimuli that trigger inflammation. This demonstrated the close connection between these two systems, Snyder says. Therefore, drugs that block iNOS activity could significantly reduce the amount of prostaglandins produced by COX-2 enzymes, he adds.

The Hopkins researchers showed the connection between the iNOS and COX-2 systems in both immune system cells and human embryonic kidney cells by adding substances known to activate these enzymes -- for example, LPS-IFN-gamma, a combination of a component of some infectious bacteria membranes and an immune system protein that targets viruses and tumors. When the researchers broke apart these cells and added antibodies that specifically bind to COX-2, tiny clumps formed that consisted of COX-2 enzymes bound to iNOS. Antibodies that bind specifically to iNOS also formed clumps of COX-2 and iNOS enzymes bound to each other.

The Hopkins team also showed that iNOS first binds to COX-2 and then makes NO. The NO chemically modifies COX-2 by a process called nitrosylation, which stimulates the enzyme to make prostaglandins. In addition, the researchers found that the same part of iNOS that binds to COX-2 also contains the "active site" of the enzyme that makes the NO. Furthermore, when the scientists blocked this dual-purpose section of iNOS, they prevented both iNOS binding to COX-2 and the subsequent activation of COX-2 by NO.

"This tells us that during reactions that cause inflammation, COX-2 and iNOS are attached to each other," Snyder said.

The team also demonstrated that the NO that exists freely in cells cannot stimulate COX-2; rather, only NO generated by iNOS that is bound directly to COX-2 can activate these enzymes to produce prostaglandins.

The other authors of the report include Sangwon Kim and Daniel Huri. This work was support by a U.S. Public Health Service grant, a Research Scientist Award (S.H.S.) and a fellowship from the Canadian Institute of Health Research .

Source: Johns Hopkins Medicine

Did you know?
A recently identified path of inflammation once thought to be wholly independent of other inflammatory systems has now been linked to another major pathway. The findings by neuroresearchers at Johns Hopkins are likely to point researchers to novel drugs that significantly reduce the risks of taking COX-2 inhibitor pain relievers, the researchers report. How To Make Cox-2 Inhibitors Safer

Asthma| Hypertension| Medicine Main| Diab french| Diabetes drug info| DruginfoFrench| Type2 diabetes| Create a dust free bedroom| Allergy statistics| Cancer terms| History of cancer| Imaging techniques| Cancer Main| Bladder cancer news| Cervix cancer news| Colon cancer news| Esophageal cancer news| Gastric cancer news| Health news| Lung cancer news| Breast cancer news| Ovarian cancer news| Cancer news|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.